Vol 9, No 1 (2012)

Articles
Metabolic and cardiovascular effects of ghrelin
., ., ., ., ., .
Abstract
Ghrelin is an endogenous ligand for growth hormone receptor, which is synthesized as a prohormone, and then proteolytically converted into 28-amino acid peptide. This peptide stimulates the secretion of growth hormone, regulates food intake, effect on carbohydrate and lipid metabolism. Ghrelin enhances the bioavailability of nitric oxide and maintains the balance between endothelin-1 and nitric oxide in the vascular wall. It increases cardiac output, and reduces blood pressure and systemic vascular resistance. Antiinflammatory effect of ghrelin is also appreciated. Since ghrelin is a circulating peptide that stimulates appetite and regulate energy balance, and its role in the development of obesity and type 2 diabetes it is the subject of intense research. A variety of metabolic functions of ghrelin requires extreme caution in the use of therapeutic approaches aimed at the stimulation or blockade of its action.
Obesity and metabolism. 2012;9(1):3-8
views
Prospects for the use of selective estrogen receptor modulator tamoxifen
., ., .
Abstract
The review presents a contemporary data concerning the use of tamoxifen in wide range of pathological conditions: central nervous system diseases and mechanisms of neuroprotective action of estrogen receptors, pituitary tumors with the accent on the treatment of prolactinomas, infertility treatment. We also discuss the risks of tamoxifen treatment for pregnancy induction in women including complications of pregnancy, fetus malformations.
Obesity and metabolism. 2012;9(1):9-13
views
The role of the sympathoadrenal system and adipokines in the development of arterial hypertension in type 2 diabetes mellitus and obesity
Pashentseva A.V.
Abstract

.

Obesity and metabolism. 2012;9(1):14-18
views
Metabolic disorders and their impact on the development of hypercoagulation syndrome in patients with Cushing's disease
., ., ., ., ., ., .
Abstract
Obesity and metabolism. 2012;9(1):19-23
views
Correction of metabolic syndrome and liver disease after biliopancreatic diversion in morbidly obese patients
., .
Abstract
The aim of this study was to analyze the corrections of the metabolic syndrome and the liver dysfunction of morbidly obese patients after the biliapancreatic diversion (BPD). All patients were divided into two groups: first group with average BMI 44,6±3,0 and second group with average BMI 53,0±6,7. After BPD the average % excess weight loss (EWL) in the first group was 72,8% and in the second - 53,2%. The corrections of the metabolic syndrome and the liver dysfunction were also better in the first group. The baseline BMI predicts the outcomes after BPD.
Obesity and metabolism. 2012;9(1):24-28
views
Effect of metformin on the bioavailability of nitric oxide in patients with type 2 diabetes
., ., ., .
Abstract
The aim of our study was to evaluate the levels of nitrite in plasma and methemoglobin in whole blood using electron paramagnetic resonance (EPR) in patients with type 2 diabetes mellitus receiving metformin. After 3 months of continuous use of the drug at a dose of 1700 mg in parallel with the improvement of carbohydrate and lipid metabolism, reduction in waist circumference there was a statistically significant increase in nitrite concentration in plasma and increased methemoglobin in whole blood. Increased bioavailability of nitric oxide during treatment with metformin may be an additional explanation for the mechanism of drug action.
Obesity and metabolism. 2012;9(1):29-33
views
The relationship of hormone-metabolic disorders and indicators of anxiety and depression in young men with obesity on different types of therapy
., ., ., ., .
Abstract
Objective: to assess hormonal and metabolic parameters and psychological status of young men with obesity. Methods: The study included 60 men with obesity (BMI>30 kg/m2) divided in two groups. Patients in the first group (n=30) received orlistat for 12 weeks (120 mg 3 times daily with meal). Patients in second group (n=30) followed hypocaloric diet and aerobic exercise. All patients were examined before treatment and after 12 weeks. Evaluation included hormonal and biochemical analyses, 48 patients were examined by psychological questionnaires (Beck Depression Inventory, Beck Anxiety Inventory, Liebowitz Social Anxiety Scale, Dutch Eating Behavior Questionnaire). Results: Patients that received orlistat treatment showed significant decrease of body mass: 50% of patients had decrease more than 5%, 30% of patients - more than 10% (p<0,05). In first group after 12 weeks of treatment level of cortisol decreased and level of testosterone increased. The results of treatment in second group were less significant. There was a significant decrease in anxiety and depression scales in patients taking orlistat (p<0,05). High levels of social anxiety did not decrease in both groups after treatment. As a result of orlistat treatment there was a decrease in external eating behavior and increase in expression of restraint eating behavior by DEBQ (p<0,05). Conclusions: treatment with orlistat reduces body weight, which is correlated by improvement of hormonal and biochemical parameters. Weight loss is accompanied by changes in rates of anxiety and depression.
Obesity and metabolism. 2012;9(1):35-41
views
Effect of lifestyle modifications for a complicated adolescent obesity
., .
Abstract
Currently, obesity has taken epidemic proportions, including adolescents. The important components of contemporary therapy of obesity in adolescents are: motivational training, modification of behavioral habits and the adolescent involvement in treatment, the effectiveness of which is demonstrated by this clinical case presentation.
Obesity and metabolism. 2012;9(1):43-45
views
Thyrotropin-Releasing Hormone Controls Mitochondrial Biology in Human Epidermis
., ., ., ., ., ., ., ., .
Abstract
Obesity and metabolism. 2012;9(1):46
views
Advantages of extended-release metformin in patients with type 2 diabetes mellitus
., .
Abstract
Obesity and metabolism. 2012;9(1):47
views
A genome-wide association meta-analysis identifies new childhood obesity loci
., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., .
Abstract
Obesity and metabolism. 2012;9(1):49
views
Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium
., ., ., ., ., ., ., ., ., ., ., ., ., ., .
Abstract
Obesity and metabolism. 2012;9(1):50
views
Endocrine and metabolic aspects of the management of patients undergoing bariatric surgery. Review of clinical recommendations.
., .
Abstract
The incidence of morbid obesity increases worldwide. Therefore surgical methods of treatment are widely applied. A lot of patients after bariatric surgery requires lifelong control and therapy. The Endocrine Society offered detailed guideline for the management of boost-bariatric surgery patients. The basic recommendations are reviewed in this article.
Obesity and metabolism. 2012;9(1):51-57
views
Leading experts in the field of endocrinology, ophthalmology and cardiology discussed current medical and social aspects of diabetes mellitus type 2 in the Republic of Tatarstan
.
Abstract
Obesity and metabolism. 2012;9(1):59-60
views
Conferences on the problems of endocrinology, obesity and metabolism in 2012
.
Abstract
Obesity and metabolism. 2012;9(1):61-62
views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies